Laboratory Business Insights Newsletter
April 2026
.png?width=1200&height=1500&name=National%20Sales%20Manager%2c%20Laboratory%20(2).png)
A Message from Jim:
Over the past year, I’ve had more conversations with laboratory leaders who feel like the rules are changing mid-game. And in many ways, they are.
What we’re seeing now isn’t just increased denials or tighter payer scrutiny—it’s a fundamental shift in how revenue is determined.
It’s no longer enough to bill correctly after the fact. Today, reimbursement depends on whether every element—documentation, ordering, compliance, and coding—can be validated before a claim is even accepted.
And now, with April 2026 regulatory updates and Q2 operational mandates, that pressure has intensified.
— Jim O’Neill
What’s Changing in 2026 (And Why It Matters)
1. Coding Complexity Is Increasing
- 17 new PLA codes (0614U–0630U) for advanced diagnostics
- Expanded infectious disease panels (e.g., COVID + Flu multiplex testing)
- Updated heavy metal testing codes (including antimony & gadolinium)
👉 Translation: More specificity = more room for error = higher denial risk
2. CLIA & Compliance Are Going Fully Digital
- Mandatory electronic-only CLIA systems
- Updated CLIA edits impacting HCPCS codes
👉 Translation: Labs must ensure compliance is embedded in workflows, not handled manually after the fact
3. PAMA Reporting & Future Reimbursement Pressure
- Reporting window: May 1 – July 31, 2026
- Covers private payer data from 2025
👉 Translation: Today’s data accuracy directly impacts future reimbursement rates
4. Reimbursement Is Being Rebalanced
- Moratorium on cuts (through Dec 2026) — temporary relief
- -2.5% efficiency adjustment impacting margins
- Site-of-service shifts favoring independent labs over hospital settings
👉 Translation: Margins are tightening—and operational efficiency is no longer optional
The Bigger Shift: Revenue Starts Before the Claim
Across molecular, toxicology, and pathology testing, payer behavior has moved upstream.
Validation now happens:
- At intake
- During ordering
- Within documentation workflows
Not after submission.
This changes everything.
The revenue cycle is no longer a back-end function—it’s a front-end discipline that determines whether revenue is achievable at all.
Schedule a Complimentary Lab Revenue Review
ADS offers a no-cost assessment to help you identify:
- Documentation and compliance gaps
- Denial trends and root causes
- Missed revenue opportunities
- Workflow inefficiencies
👉 Schedule Your Lab Revenue Review Today
Where Revenue Is Slipping
We continue to see the same pattern across laboratories:
- Missing documentation before submission
- Incorrect or incomplete coding for new test panels
- Claims never submitted due to front-end gaps
- Underpayments that go undetected
These are not major breakdowns.
They are small, preventable gaps—but in today’s environment, they are:
- Harder to detect
- Harder to correct
- And often impossible to recover
See how AI and automation are supporting laboratory workflow efficiency
What Leading Labs Are Doing Differently
Top-performing labs are not just improving billing.
They are restructuring their entire revenue workflow:
- Capturing documentation at the point of order
- Validating medical necessity in real-time
- Applying payer-specific rules upfront
- Reducing manual variability with automation
The result:
✔ More predictable revenue
✔ Faster turnaround times
✔ Fewer denials
✔ Stronger compliance posture
How ADS Helps Labs Navigate This Shift
This is exactly where Advanced Data Systems Corporation (ADS) is focused.
ADS’s laboratory billing software and RCM solutions are built for this new, proof-driven environment—helping labs move from reactive billing to proactive revenue capture.
Key Capabilities Include:
- Front-End Validation: Ensure documentation, coding, and medical necessity are complete before submission
- Automated Coding Updates: Stay current with evolving CPT, HCPCS, and PLA codes
- Denial Prevention Intelligence: Identify risks before they become lost revenue
- Real-Time Visibility: Track performance across the entire revenue lifecycle
- Integrated Compliance Workflows: Align with CLIA, PAMA, and CMS requirements automatically
👉 In short: ADS helps labs get it right the first time—every time
👉 Explore ADS Laboratory Billing Solutions:
https://www.adsc.com/laboratory-billing-software
Things to Think On...
The lab revenue cycle hasn’t just become more complex—it’s become more precise.
And now, with regulatory changes, digital mandates, and evolving reimbursement models, precision is the difference between growth and loss.
Success is no longer defined by how quickly issues are corrected.
It’s defined by how effectively they are prevented.
P.S.
Many labs are surprised to find their greatest revenue risk isn’t in billing—
It’s in the steps that happen before the claim is ever created.
Explore features designed to support laboratory billing performance and workflow efficiency
Keep up with the latest laboratory billing trends, insights, and industry news
Medical Billing / RCM | Laboratory
Billing Laboratory Tests Without LCDs: How Labs Can Stay Profitable Despite Coverage Gaps
By Jim O'Neill
on February 18th, 2026
Medical Billing / RCM | Laboratory
DOJ Enforcement of Clinical Laboratories: What Lab CFOs and Compliance Managers Need to Know Now
For clinical laboratories, compliance risk is no longer confined to the legal department. It is now ...
By Jim O'Neill
on February 11th, 2026
Medical Billing / RCM | Laboratory
Major PAMA Updates for 2026: What Clinical Laboratories Need to Know Now
Laboratory reimbursement is back in the spotlight and the stakes are higher than ever before.
By Jim O'Neill
on February 5th, 2026
Disclaimer: Articles and content about governmental information, such as CMS, Medicare, and Medicaid, are presented according to our best understanding. Please visit www.cms.gov for any necessary clarifications are needed. We are not responsible for typographical errors or changes that may have occurred after this newsletter was produced. Visit www.adsc.com to view our most up-to-date information. We don’t endorse any companies or organizations mentioned in our newsletters; you are encouraged to do research and due diligence on any that might interest you.